

Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
47508-518
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal, et al.Filing Date
2/6/2001Group Art Unit
1635

Sheet 1 OF 2

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,510,239	4/23/96	Baracchini, et al.			

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO94/23028	10/13/1994	WO				
	WO96/12497	5/2/1996	WO				
	WO97/11171	3/27/1997	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

A1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in <u>Applied Antisense Oligonucleotide Technology</u> (Stein and Krieg, Eds.), pp. 365-385 (1998)
A2	Agrawal, "Preface", in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. v-vii (1996)
A3	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in <u>Methods in Molecular Medicine: Antisense Therapeutics</u> (Agrawal, Ed.); pp. 247-270 (1996)
A4	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
A5	Crooke; "Basic Principles of Antisense Therapeutics"; in <u>Antisense Research and Application</u> (Crooke, Ed.); pp. 1-50 (1998)
A6	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
B1	Friedmann; "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not conformance and not considered. Include copy with next communication to applicant.

RECEIVED

BOSTON 1514336v1

OCT 10 2002

TECH CENTER 1600/2900



Subt. For, PTO-1449				Docket Number 47508-518 HYZ-030CPCN3		Application Number 09/777,526	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Agrawal, et al.			
				Filing Date 2/6/2001		Group Art Unit 1635	
Sheet	2	OF	2				

	B2	Monia, et al.; "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase"; Nature Medicine; Vol. 2, No. 6, pp. 668-675, June 1996
	B3	Schofield et al.; "Non-viral Approaches to Gene Therapy"; British Medical Bulletin; Vol. 51, No. 1, pp. 56-71 (1995)
	B4	Verma, et al.; "Gene Therapy – Promises, Problems, and Prospects"; Nature; Vol. 389, pp. 239-242, September 1997
	B5	Vlassov, et al.; "In Vivo Pharmacokinetics of Oligonucleotides Following Administration by Different Routes"; in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> (Akhtar, Ed.); pp. 71-83 (1995).
	B6	Vlassov, et al.; "Penetration of Oligonucleotides into Mouse Organism through Mucosa and Skin"; FEBS Letters; Vol. 327, No. 3, pp. 271-274; August 1993
	B7	
	B8	
	B9	
	B10	
	B11	
	B12	
	B13	
	B14	
	B15	
	C1	
	C2	
	C3	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	D1	
	D2	
	D3	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

RECEIVED
OCT 10 2002
TECH CENTER 1600/2900